Waldenström's macroglobulinemia: A review of therapy

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Waldenström's macroglobulinemia is a lymphoplasmacytic disorder characterized by a monoclonal IgM protein, anemia, hepatosplenomegaly, and hyperviscosity. With the increasing use of screening chemistry evaluations, many patients are diagnosed without symptoms and are candidates for observation with no therapeutic intervention until symptoms develop. Plasma exchange can be useful to manage hyperviscosity but does not address the infiltrative process in the bone marrow, which requires cytoreductive therapy. This review covers current regimens that have been used to manage Waldenström's macroglobulinemia, including alkylating agents, purine nucleoside analogs, and rituximab. The value of steroids, radiotherapy, stem cell transplantation, and splenectomy is also reviewed. The lack of phase III studies does not permit an algorithm that would be appropriate for all patients. Treatment needs to be individualized based on patient age, the clinical manifestations of Waldenström's, and the patient's potential for developing toxic side effects of the selected treatment regimen.

Original languageEnglish (US)
Pages (from-to)1517-1526
Number of pages10
JournalLeukemia and Lymphoma
Volume43
Issue number8
DOIs
StatePublished - Aug 8 2002

Fingerprint

Waldenstrom Macroglobulinemia
Purine Nucleosides
Plasma Exchange
Poisons
Alkylating Agents
Stem Cell Transplantation
Splenectomy
Therapeutics
Immunoglobulin M
Anemia
Radiotherapy
Bone Marrow
Steroids
Observation
Proteins

Keywords

  • Alkylating agents
  • Lymphoplasmacytic disorder
  • Monoclonal IgM protein
  • Purine nucleoside analogs
  • Waldenström's macroglobulinemia

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Waldenström's macroglobulinemia : A review of therapy. / Gertz, Morie.

In: Leukemia and Lymphoma, Vol. 43, No. 8, 08.08.2002, p. 1517-1526.

Research output: Contribution to journalArticle

@article{d45acb78111d4cb68f090b21dfd7093a,
title = "Waldenstr{\"o}m's macroglobulinemia: A review of therapy",
abstract = "Waldenstr{\"o}m's macroglobulinemia is a lymphoplasmacytic disorder characterized by a monoclonal IgM protein, anemia, hepatosplenomegaly, and hyperviscosity. With the increasing use of screening chemistry evaluations, many patients are diagnosed without symptoms and are candidates for observation with no therapeutic intervention until symptoms develop. Plasma exchange can be useful to manage hyperviscosity but does not address the infiltrative process in the bone marrow, which requires cytoreductive therapy. This review covers current regimens that have been used to manage Waldenstr{\"o}m's macroglobulinemia, including alkylating agents, purine nucleoside analogs, and rituximab. The value of steroids, radiotherapy, stem cell transplantation, and splenectomy is also reviewed. The lack of phase III studies does not permit an algorithm that would be appropriate for all patients. Treatment needs to be individualized based on patient age, the clinical manifestations of Waldenstr{\"o}m's, and the patient's potential for developing toxic side effects of the selected treatment regimen.",
keywords = "Alkylating agents, Lymphoplasmacytic disorder, Monoclonal IgM protein, Purine nucleoside analogs, Waldenstr{\"o}m's macroglobulinemia",
author = "Morie Gertz",
year = "2002",
month = "8",
day = "8",
doi = "10.1080/1042819021000002839",
language = "English (US)",
volume = "43",
pages = "1517--1526",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Waldenström's macroglobulinemia

T2 - A review of therapy

AU - Gertz, Morie

PY - 2002/8/8

Y1 - 2002/8/8

N2 - Waldenström's macroglobulinemia is a lymphoplasmacytic disorder characterized by a monoclonal IgM protein, anemia, hepatosplenomegaly, and hyperviscosity. With the increasing use of screening chemistry evaluations, many patients are diagnosed without symptoms and are candidates for observation with no therapeutic intervention until symptoms develop. Plasma exchange can be useful to manage hyperviscosity but does not address the infiltrative process in the bone marrow, which requires cytoreductive therapy. This review covers current regimens that have been used to manage Waldenström's macroglobulinemia, including alkylating agents, purine nucleoside analogs, and rituximab. The value of steroids, radiotherapy, stem cell transplantation, and splenectomy is also reviewed. The lack of phase III studies does not permit an algorithm that would be appropriate for all patients. Treatment needs to be individualized based on patient age, the clinical manifestations of Waldenström's, and the patient's potential for developing toxic side effects of the selected treatment regimen.

AB - Waldenström's macroglobulinemia is a lymphoplasmacytic disorder characterized by a monoclonal IgM protein, anemia, hepatosplenomegaly, and hyperviscosity. With the increasing use of screening chemistry evaluations, many patients are diagnosed without symptoms and are candidates for observation with no therapeutic intervention until symptoms develop. Plasma exchange can be useful to manage hyperviscosity but does not address the infiltrative process in the bone marrow, which requires cytoreductive therapy. This review covers current regimens that have been used to manage Waldenström's macroglobulinemia, including alkylating agents, purine nucleoside analogs, and rituximab. The value of steroids, radiotherapy, stem cell transplantation, and splenectomy is also reviewed. The lack of phase III studies does not permit an algorithm that would be appropriate for all patients. Treatment needs to be individualized based on patient age, the clinical manifestations of Waldenström's, and the patient's potential for developing toxic side effects of the selected treatment regimen.

KW - Alkylating agents

KW - Lymphoplasmacytic disorder

KW - Monoclonal IgM protein

KW - Purine nucleoside analogs

KW - Waldenström's macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=0036020951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036020951&partnerID=8YFLogxK

U2 - 10.1080/1042819021000002839

DO - 10.1080/1042819021000002839

M3 - Article

C2 - 12400593

AN - SCOPUS:0036020951

VL - 43

SP - 1517

EP - 1526

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 8

ER -